Preclinical studies of opioids and opioid antagonists on gastrointestinal function
- 8 September 2004
- journal article
- review article
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 16 (s2) , 46-53
- https://doi.org/10.1111/j.1743-3150.2004.00555.x
Abstract
Opioid receptors in the gastrointestinal (GI) tract mediate the effects of endogenous opioid peptides and exogenously administered opioid analgesics, on a variety of physiological functions associated with motility, secretion and visceral pain. The studies reviewed or reported here describe a range of in vivo activities of opioid receptor antagonists upon GI function in rodents, focusing on mu receptors. Naloxone, and the peripherally acting mu-opioid receptor antagonists alvimopan and methylnaltrexone, reverse morphine-induced inhibition of GI transit in mice and rats, and morphine- or loperamide-induced inhibition of castor oil-induced diarrhoea in mice. At doses producing maximal reversal of morphine-induced effects upon GI transit, only the central nervous system (CNS) penetrant antagonist naloxone was able to reverse morphine-induced analgesia. Both central and peripheral opioid antagonists may affect GI function and/or visceromotor sensitivity in the absence of exogenous opioid analgesics, suggesting a constitutive role for endogenous opioid peptides in the control of GI physiology. Furthermore, in contrast to naloxone, alvimopan does not produce hypersensitivity to the visceromotor response induced by nociceptive levels of colorectal distension in a rodent model of post-inflammatory colonic hypersensitivity, suggesting that in the periphery endogenous mu-opioid receptor-mediated mechanisms do not regulate colonic sensitivity. The data support the hypothesis that peripherally acting opioid antagonists may be able to selectively block opioid receptors in the GI tract, thereby preserving normal GI physiology, while not blocking the effects of endogenous opioid peptides or exogenous opioid analgesics in the CNS. These findings suggest that the primary sites of action of mu-opioid agonists with respect to inhibition of GI function are in the periphery, whereas analgesic activity resides primarily in the CNS.Keywords
This publication has 54 references indexed in Scilit:
- The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modellingNeurogastroenterology & Motility, 2004
- Arylacetamide κ-Opioid Receptor Agonists Produce a Tonic- and Use-Dependent Block of Tetrodotoxin-Sensitive and -Resistant Sodium Currents in Colon Sensory NeuronsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Opioid-Induced Bowel DysfunctionDrugs, 2003
- Methylnaltrexone: Investigation of clinical applicationsDrug Development Research, 2000
- Peripheral Opioid Modulation of Visceral PainaAnnals of the New York Academy of Sciences, 2000
- Reversal by K-agonists of peritoneal irritation-induced ileus and visceral pain in ratsLife Sciences, 1997
- Spinal mu and delta, but not kappa, opioid-receptor agonists attenuate responses to noxious colorectal distension in the ratPain, 1995
- Contrasting Actions of Intrathecal U50, 488H, Morphine, or [D-Pen sup 2, D-Pen sup 5] Enkephalin or Intravenous U50, 488H on the Visceromotor Response to Colorectal Distension in the RatAnesthesiology, 1995
- LoperamideDigestive Diseases and Sciences, 1993
- Physiologische und pharmakologische Versuche über die DünndarmperistaltikNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1917